Results 121 to 130 of about 2,060,078 (325)
Barriers and enablers to the implementation of patient-reported outcome and experience measures (PROMs/PREMs): protocol for an umbrella review
Systematic ReviewsBackground Patient-reported outcome and experience measures (PROMs and PREMs, respectively) are evidence-based, standardized questionnaires that can be used to capture patients’ perspectives of their health and health care.Guillaume Fontaine, Marie-Eve Poitras, Maxime Sasseville, Marie-Pascale Pomey, Jérôme Ouellet, Lydia Ould Brahim, Sydney Wasserman, Frédéric Bergeron, Sylvie D. Lambert +8 moredoaj +1 more sourceDesign and introduction of a quality of life assessment and practice support system: perspectives from palliative care settings [PDF]
, 2018 Background:
Quality of life (QOL) assessment instruments, including patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs), are increasingly promoted as a means of enabling clinicians to enhance person-centered care.Hilliard, Neil, Krawczyk, Marian, Laforest, Esther, McLeod, Barbara, Reimer-Kirkham, Sheryl, Robin Cohen, S., Sawatzky, Richard, Schick-Makaroff, Kara, Stajduhar, Kelli, Tayler, Carolyn, Öhlén, Joakim +10 morecore +2 more sourcesPotential therapeutic targeting of BKCa channels in glioblastoma treatment
Molecular Oncology, EarlyView.This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk +4 morewiley +1 more sourceStrategies for incorporating patient-reported outcomes in the care of people with chronic kidney disease (PRO kidney): a protocol for a realist synthesis
Systematic Reviews, 2019 Background Patient-reported outcomes and experience measures (jointly referred to here as PROs) are internationally recognized as a means for patients to provide information about their quality of life, symptoms, and experiences with care.Kara Schick-Makaroff, Onouma Thummapol, Stephanie Thompson, Rachel Flynn, Mehri Karimi-Dehkordi, Scott Klarenbach, Richard Sawatzky, Joanne Greenhalgh +7 moredoaj +1 more sourceRemote working: survey of attitudes to eHealth of doctors and nurses in rural general practices in the United Kingdom.
, 2005 BACKGROUND: Health professionals in rural primary care could gain more from eHealth initiatives than their urban counterparts, yet little is known about eHealth in geographically isolated areas of the UK.Brebner, Eileen, Godden, David, King, Gerry, McNicol, Iain, Reid, Margaret, Richards, Helen, Selvaraj, Sivasubramaniam +6 morecore +1 more sourceEstablishing a core outcome set for peritoneal dialysis : report of the SONG-PD (standardized outcomes in nephrology-peritoneal dialysis) consensus workshop [PDF]
, 2020 Outcomes reported in randomized controlled trials in peritoneal dialysis (PD) are diverse, are measured inconsistently, and may not be important to patients, families, and clinicians.Abraham, Georgi, Abu Alfa, Ali, Anumudu, Samaya, Au, Eric, Azukaitis, Karolis, Bargman, Joanne, Baumgartf, Amanda, Bernays, Sarah, Bernier-Jean, Amelie, Blake, Peter, Boudville, Neil, Brown, Edwina, Brown, Edwina A., Brunier, Gillian, Brunier, Gillian, Butt, Zeeshan, Carter, Simon A., Chen, Jenny, Cheung, Catherine, Cho, Yeoungjee, Cho, Yeoungjee, Craig, Jonathan, Craig, Jonathan C., Crowe, Sally, Cueto Manzano, Alfonso, da Silva, Viviane Calice, Davies, Simon, Dong, Jie, Dong, Jie, Dunn, Louese, Dunning, Tony, Evangelidis, Nicole, Figueiredo, Ana, Finkelstein, Fred, Germino, Greg, Goffin, Eric, Goh, Bak Leong, Guha, Chandana, Gutman, Talia, Gutman, Talia, Hanson, Camilla, Hemmelgarn, Brenda, Howell, Martin, Htay, Htay, Hurst, Helen, Ito, Yasuhiko, Jassal, Vanita, Jha, Vivekanand, Johnson, David, Johnson, David W., Ju, Angela, Kawanishi, Hideki, Kelly, Amy, Kelly, Ayano, Kilonzo, Kajiru Gad, Kim, Yong-Lim, Krishnan, Mahesh, Lambie, Mark, Levin, Adeera, Li, Philip Kam-Tao, Lichodziejewska-Niemierko, Monika, Liew, Adrian, Logeman, Charlotte, Maner, Karine, Manera, Karine E., Mann, Neelam, Manns, Braden, Matus, Andrea, McGee, Richard, Mehrotra, Rajnish, Mehrotra, Rajnish, Mendelson, Asher, Morelle, Johann, Nadeau-Fredette, Annie-Claire, Naicker, Sarala, Naicker, Saraladevi, Nataatmadja, Melissa, Nessim, Sharon, Neu, Alicia, Neumann, Joanna, Nourse, Peter, O'Lone, Emma, Oliver, Matthew, Pecoits-Filho, Roberto, Perl, Jeffrey, Perl, Jeffrey, Quinn, Robert, Robinson, Bruce, Rutherford, Claudia, Sanabria, Mauricio Rafael, Sautenet, Benedicte, Saxena, Anjali, Scholes-Robertson, Nicole, Schreiber, Martin, Schwartz, Daniel, Sharma, Ankit, Shen, Jenny, Shen, Jenny I., Sumpton, Daniel, Sweety, Soheli Ahmed, Szeto, Cheuk-Chun, Teitelbaum, Isaac, Teixeira-Pinto, Armando, Teo, Sharon, Toffelmire, Ted, Tong, Allison, Tugwell, Peter, Van Biesen, Wim, Van, Kim Linh, Verdin, Nancy, Viecelli, Andrea, Wang, Angela Yee-Moon, Wheeler, David, Wilkie, Martin, Wilkie, Martin, Wilson, Scott, Winkelmayer, Wolfgang, Yap, Hui Kim, Yeates, Karen +118 morecore +2 more sourcesIdentification of patient-reported outcomes measures (PROMs) and patient-reported experiences measures (PREMs) in Gaucher disease in Spain
Medicina ClínicaPatient-reported outcome measures (PROMs) and patient-reported experiences measures (PREMs) are crucial for understanding the impact of GD on quality of life and patient's perceptions on care, but also to guide decision-making processes. Nevertheless, no specific PREMs in GD have been published, neither PROMs for Spanish GD patients have been developed.Giraldo P, Camprodón M, Alcolea PC, Gras-Colomer E, Ibarretxe D, Lakhwani S, Mora E, Calderón MPV, Morales-Conejo M +8 moreopenaire +3 more sourcesEffective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet +17 morewiley +1 more sourceMonitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer
Molecular Oncology, EarlyView.Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien +35 morewiley +1 more source
